Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy.

On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge fund, Parvus Asset Management, building a stake in the company, as ...

Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34% By Annika Kim Constantino, CNBC • Published June 23, 2025 • Updated on June 23, 2025 at 4:01 pm ...

Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy ...

Novo Nordisk has an estimated 62% market share of the GLP-1 agonist market, with archrival Eli Lilly accounting for another 35%. Investors are looking ahead to next-generation drugs that could ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say the company's cautious culture is to blame.

Overall revenues at Novo Nordisk — which also produces diabetes and rare disease treatments — rose 18% to 78.09 billion Danish kroner versus an expected 78.18 million Danish kroner.

Novo Nordisk will cover all development costs and lead commercialization. Price Action: NVO shares are trading lower by 3.87% to $63.64 premarket at the last check on Friday. Read Next: ...

Following the success of its treatments, Novo Nordisk rose to become Europe’s most valuable company by market capitalisation in September 2023, overtaking French luxury fashion house LVMH ...

Novo Nordisk's share price fell as well on Monday. However, the big pharma stock tumbled only around 5%, reflecting a much more muted impact on its business from scrapping the deal with Hims & Hers.